Heme is built from 5-aminolevulinic acid through a chain of enzymatic steps that ends when iron is inserted into protoporphyrin. The liver adjusts its heme output through the first enzyme, ALA synthase 1, which drugs and alcohol push up; fasting makes the pathway more sensitive to those inducers. When a later enzyme runs at partial capacity, that extra demand piles the early precursors (ALA and porphobilinogen) up behind the block; ALA toxicity is the leading explanation for the neurologic features of an acute attack. Several blocks further down build up porphyrins that cause skin lesions instead.
- → 5-aminolevulinic acid (ALA): ALA synthase, ALAS1 in every tissue (the step the liver induces) and ALAS2 only in the red cell precursors of the marrow.
- ALA → porphobilinogen (PBG): ALA dehydratase (ALAD). Inhibited by succinylacetone in tyrosinemia type 1, whose own enzyme defect lies in tyrosine breakdown, not in the heme pathway.
- four PBG → hydroxymethylbilane: porphobilinogen deaminase, also called hydroxymethylbilane synthase (HMBS). Blocked in acute intermittent porphyria.
- hydroxymethylbilane → uroporphyrinogen III: uroporphyrinogen III synthase (UROS).
- uroporphyrinogen III → coproporphyrinogen III: uroporphyrinogen decarboxylase (UROD).
- coproporphyrinogen III → protoporphyrinogen: coproporphyrinogen oxidase (CPOX).
- protoporphyrinogen → protoporphyrin: protoporphyrinogen oxidase (PPOX).
- protoporphyrin + iron → heme: ferrochelatase (FECH).
- Acute intermittent porphyria (autosomal dominant, low penetrance): one working copy of HMBS leaves about half the enzyme, enough until the liver is asked for more heme. Then ALA and PBG accumulate, giving severe abdominal pain, neuropathy, autonomic and psychiatric signs, and red urine that darkens on standing, without skin disease. Attacks are commoner in women. IV hemin treats an attack; givosiran, which silences ALAS1 in the liver, lowers ALA and PBG and prevents recurrent attacks.
- Tyrosinemia type 1: this is a secondary effect, not a deficiency of a heme enzyme. The primary defect is fumarylacetoacetate hydrolase in tyrosine breakdown; the succinylacetone it produces inhibits ALA dehydratase, so ALA rises and can provoke acute neurologic crises like those of acute intermittent porphyria.
- Also on this pathway, without a page here yet: ALA dehydratase deficiency porphyria (recessive; high ALA with normal PBG); hereditary coproporphyria (CPOX) and variegate porphyria (PPOX), acute porphyrias that can also cause skin lesions; and congenital erythropoietic porphyria (UROS; porphyrins in skin and bone with hemolysis), porphyria cutanea tarda (low liver UROD activity, mostly acquired and iron related, with a heterozygous UROD variant in about 20%; highly carboxylated porphyrins in urine), and erythropoietic protoporphyria (FECH; free protoporphyrin in red cells).
- Urine PBG is the test for an acute attack: a PBG-to-creatinine ratio at least 10 times the upper limit of normal with typical symptoms. It is raised substantially only in AIP, hereditary coproporphyria, and variegate porphyria. In these acute hepatic porphyrias the partial block becomes rate limiting when the liver is pushed to make more heme, so ALA and PBG back up; the cutaneous porphyrias, though also past the PBG step, do not raise it.
- High ALA with normal PBG points before the PBG step: ALA dehydratase deficiency, or succinylacetone from tyrosinemia type 1.
- Stool and plasma porphyrins separate the three PBG-raising porphyrias: mostly coproporphyrin III in stool for hereditary coproporphyria; coproporphyrin III and protoporphyrin in roughly equal amounts in stool, with a plasma fluorescence peak near 626 nm, for variegate porphyria.
- A normal red cell PBG deaminase activity does not exclude AIP: variants in exon 1 spare the red cell form of the enzyme.
The 5 P's of AIP: Pain (abdominal), Psychiatric signs, Polyneuropathy, Pee that darkens, and Precipitants such as medications and the menstrual period.